US Stock Insider Trading | Recursion disclosed 6 insider transactions on February 19

K-LinePoet · 2026-02-20T02:08:57+00:00

Recursion Pharmaceuticals disclosed multiple insider transactions on February 19, 2026, with Director Gibson Christopher selling 40,000 shares on that day, and other executives also engaging in multiple sell-offs. The company focuses on drug discovery, utilizing its recursive operating system for data analysis and relationship exploration.

K-LinePoet

2026-02-20 02:08:57

Abstract generation in progress

On February 19, 2026, Recursion (RXRX) disclosed six insider trading transactions. Director Gibson Christopher sold 40,000 shares.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 19, 2026	Executive	Taylor Ben R	February 17, 2026	Sell	11,900	3.49	41,600
February 19, 2026	Director	Gibson Christopher	February 19, 2026	Sell	40,000	3.46	138,400
February 19, 2026	Director	Khan Najat	February 17, 2026	Sell	14,300	3.49	49,800
February 19, 2026	Executive	Taylor Ben R	February 18, 2026	Sell	13,400	3.08	41,400
February 19, 2026	Executive	Hallett David	February 17, 2026	Sell	11,900	3.49	41,600
February 19, 2026	Director	Gibson Christopher	February 17, 2026	Sell	27,300	3.49	95,200
February 10, 2026	Director	Khan Najat	February 6, 2026	Sell	10,400	3.98	41,200
February 10, 2026	Executive	Taylor Ben R	February 6, 2026	Sell	11,400	3.98	45,400
February 10, 2026	Executive	Hallett David	February 6, 2026	Sell	11,400	3.98	45,400
February 6, 2026	Director	Borgeson Blake	February 3, 2026	Sell	220,000	4.20	924,000

[Company Profile]

Recursion Pharmaceuticals, Inc. was originally founded on November 4, 2013, and incorporated in Delaware. The company is a leading clinical-stage TechBio firm that decodes biology to industrialize drug discovery. The core mission of the company is the Recursive Operating System (OS), a platform built across multiple technologies that enables the company to map and navigate trillions of biologically, chemically, and patient-centric relationships within over 50 PB of proprietary data. The company frames this integration of physical and digital components as an iterative cycle, where scaled “wet lab” biological, chemical, and patient-centered experimental data are organized by “dry lab” computational tools to identify, validate, and translate therapeutic insights.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes